News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves Teva Pharmaceutical Industries Limited (TEVA) Copycat of Amgen (AMGN)'s Neupogen


8/30/2012 7:31:36 AM

U.S. drug regulators gave the nod to a Teva Pharmaceutical Industries drug that boosts the production of infection-fighting white blood cells in certain cancer patients receiving chemotherapy. Teva's medicine is in many ways a copy of Amgen Inc's biologic drug Neupogen, which faces the expiration of its U.S. patent next year. In an a settlement of patent litigation, Teva agreed last year to refrain from launching its versions of Neupogen and Neulasta, Amgen's longer-lasting white blood cell booster, in the United States until November 2013.

Read at Reuters
Read at CNBC
Read at EconomicTimes
Read at Globes Online
Read at News Release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES